Research programme: cancer therapeutics - CytoriAlternative Names: ATI-0721; ATI-1150; ATI-1186; ATI-1230
Latest Information Update: 18 Feb 2017
At a glance
- Originator Azaya Therapeutics
- Developer Cytori Therapeutics
- Mechanism of Action DNA topoisomerase I inhibitors; Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Scleroderma
- Discontinued Cancer